StockVS

RadNet, Inc. (RDNT) Analyse boursière

Santé

RadNet, Inc.

$54.12

$-0.28 (-0.51%)

Dernière mise à jour : 26 mai 2026

Historique des Prix

Analyse

Présentation de l'entreprise

RadNet, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing outpatient diagnostic imaging services across the United States and internationally. The company's operational footprint is divided into two primary segments, Imaging Centers and Digital Health, offering a comprehensive suite of services that include magnetic resonance imaging, computed tomography, positron emission tomography, and other advanced diagnostic procedures. This significant enterprise is currently valued at a market capitalization of $4.34 billion, generating annual revenue of $2.04 billion, and employing a workforce of 8,844 individuals. The substantial market cap combined with the robust revenue stream of over two billion dollars indicates that RadNet occupies a notable position in the competitive landscape of diagnostic imaging, reflecting investor confidence in its scale and operational reach despite current profitability challenges.

Santé financière

The company reported a revenue of $2.04 billion for the trailing twelve months, yet it posted a net income of -$18.652 million, revealing a cost structure where operating expenses and provisions significantly eroded the bottom line before arriving at a net loss. Despite the negative net income, the entity maintained an EBITDA of $242.93 million, suggesting that core operational cash generation remains positive even when accounting for interest and taxes. This positive EBITDA contrasts sharply with the net loss, highlighting that the company's cost structure includes substantial non-operational expenses or significant interest burdens that impact the final profit figure. In terms of liquidity, RadNet generated free cash flow of $180.29 million, which provides a crucial buffer for financial flexibility, allowing the company to fund operations, invest in technology, or manage debt obligations without immediate external financing. The balance sheet shows a cash balance of $767.21 million against total debt of $1.86 billion, resulting in a debt-to-equity ratio of 137.09%, which characterizes the balance sheet as highly leveraged rather than conservative. Although the company carries significant debt, the current ratio stands at 1.76, indicating a healthy short-term liquidity position where current assets exceed current liabilities by a comfortable margin. Return on equity is recorded at 1.4% and return on assets at 1.6%, metrics that reveal limited management effectiveness in generating returns on the capital base, particularly given the negative net income and high leverage levels present in the firm's financial structure.

Évaluation de la valorisation

The valuation metrics present a complex picture, with the trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E stands at 55.36. The absence of a trailing P/E and the elevated forward P/E imply that the market is pricing in a significant expected turnaround in earnings trajectory, anticipating future profitability that has not yet materialized in the historical data. The price-to-book ratio is 3.97, indicating that the market values the company at a substantial premium over its book value, which often reflects growth expectations or intangible assets not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 2.13 and the EV/EBITDA of 23.45 suggest that the stock is trading at a premium relative to its revenue and earnings before interest, taxes, depreciation, and amortization, consistent with the high forward P/E multiple. In terms of trading range, the 52-week high is $85.84 and the 52-week low is $46.76, meaning the current share price sits within this historical volatility band, reflecting market sentiment shifts over the past year. The beta value is 1.53, which signifies that the stock price is more volatile than the broader market, exhibiting approximately 53% higher sensitivity to market movements compared to an average equity.

Growth & Income

RadNet, Inc. demonstrated revenue growth of 14.8% year-over-year, while earnings growth is listed as N/A due to the recent net loss. The divergence between strong revenue expansion and the absence of earnings growth indicates that the company is currently in a phase of reinvestment or restructuring where top-line gains have not yet translated into bottom-line profitability, implying that profitability recovery is a future objective rather than a current reality. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, reflecting a strategy of retaining all earnings to fund operations and growth initiatives rather than distributing income to shareholders. Consequently, the company's overall growth and income profile is characterized by aggressive top-line expansion and a high-reinvestment approach, foregoing current income distribution to potentially enhance future earnings potential and operational scale.

Comparaison avec les pairs

RadNet, Inc. (RDNT) opère dans le secteur Diagnostics et Recherche. Voici comment il se compare à ses pairs les plus proches par capitalisation boursière :

Entreprise Ticker Cap. Boursière Ratio P/E
RadNet, Inc. RDNT $4.28B N/A
Thermo Fisher Scientific Inc. TMO $166.55B 24.6
Danaher Corporation DHR $122.31B 33.4
IDEXX Laboratories, Inc. IDXX $43.95B 41.0

Le ratio P/E moyen du secteur Diagnostics et Recherche est de 32.5x. RadNet, Inc. se négocie à un P/E de N/A.

Cette analyse est générée par IA à titre informatif uniquement et ne constitue pas un conseil financier. Les données peuvent être retardées ou inexactes. Faites toujours vos propres recherches et consultez un conseiller financier qualifié avant de prendre des décisions d'investissement.

À propos de RadNet, Inc.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

La description de l'entreprise est affichée en anglais.

Visiter le site →

Statistiques Clés

Capitalisation
$4.28B
Ratio P/E
N/A
Plus Haut 52 Sem.
$85.84
Plus Bas 52 Sem.
$50.76
Volume Moyen
880.45K
Bêta
1.43

Données fournies par Yahoo Finance via yfinance. Mis à jour quotidiennement.

Info Entreprise

Bourse
NASDAQ
Pays
United States
Employés
11,000